
Merck & Company (MRK): KEYTRUDA Growth vs. Patent Risk
Merck is a Buy as KEYTRUDA still drives growth, WINREVAIR is scaling fast, and the pipeline offers a path through the 2028 patent transition. The stock remains a transition story, but new products and late-stage oncology assets support the case.





